Highlights of Dr. David Hunter’s Oral Presentation at ACR’s Late Breaking Abstracts Session

2 years ago

SOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, Nov. 20, 2023 (GLOBE NEWSWIRE) -- Professor David Hunter, Florance and Cope Chair…

Update on the merger approval process for the combination of Novozymes and Chr. Hansen: The parties have submitted a remedy proposal to the European Commission.

2 years ago

November 20, 2023 Please see attachment. Contact information Investor RelationsAnders Mohr Christensen+45 2515 2364dkamc@chr-hansen.com Press RelationsSanne Seyer-Hansen+45 6038 6207dksash@chr-hansen.com Attachment…

Update on merger EC offered remedy proposal

2 years ago

Read the full announcement in PDF Attachment Update on merger EC offered remedy proposal

Novartis showcases significant data updates from Kisqali®, iptacopan and Scemblix® at SABCS and ASH

2 years ago

Late-breaking final iDFS analysis from NATALEE investigating Kisqali® (ribociclib) in broad population of patients with stage II and III HR+/HER2-…

Continued strong Cresemba® (isavuconazole) sales performance in Asia Pacific and China triggers third sales milestone payment for the region from Pfizer this year

2 years ago

Allschwil, Switzerland, November 20, 2023 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs…

Oxurion Discloses Topline Data from KALAHARI Phase 2, Part B Trial of Novel PKal Inhibitor THR-149 in Diabetic Macular Edema

2 years ago

  Regulated information – Inside information Despite Prior Positive Data, THR-149 Did Not Demonstrate Improvement in Vision Oxurion’s Board has…

Tryp Therapeutics Announces Closing of Oversubscribed Private Placement of Unsecured Convertible Notes for Gross Proceeds of AUD$3,215,000

2 years ago

KELOWNA, BC / ACCESSWIRE / November 20, 2023 / Tryp Therapeutics Inc. ("Tryp" or the "Company") (CSE:TRYP), a clinical-stage biotechnology…

Third Party Withdraws Appeal Related to Cantargia Patent

2 years ago

LUND, SE / ACCESSWIRE / November 20, 2023 / Cantargia (STO:CANTA) Cantargia (Cantargia AB; Nasdaq Stockholm: CANTA) today reported that…

BioNxt Accelerates Cladribine ODF Clinical and Commercialization Strategy for Multiple Sclerosis Treament

2 years ago

VANCOUVER, BC / ACCESSWIRE / November 20, 2023 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT) is pleased to…